Genmab AS

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

26.61%

Market Cap

14.35 Bil.

P/E Ratio

19.78

Dividend Yield

0.00 %

Earnings per Share

13.76 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE247.5 G0 Units
PRICE DETERMINATION TIME07/21/2026 / 09:57:14 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW249242.2
PREV. DAY'S PRICE241.2 (07/20)
CHANGE DAY BEFORE
+6.30
2.61 %
52 WEEK HIGH / LOW304.5 (01/15)180.4 (08/11)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
8.9516.3913.769.6614.40
DIVIDENDS PER SHARE
0.000.000.000.000.00
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
32.3412.2119.7825.5717.16
PRICE - BOOK RATIO
4.452.583.36--
PRICE - SALES RATIO
8.624.485.17--
PRICE - CASH FLOW RATIO
19.2512.4116.20--
Further Key Figures

Master Data

WKN
565131
ISIN
DK0010272202
SYMBOL
GE9
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
GENMAB
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
Danish Krone
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
59.49 Mil.
MARKET CAPITALISATION
14.35 Bil.

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-4.55 %
10.59 %
2.29 %
-9.53 %
26.61 %
-34.67 %
-34.13 %
-10.37 %
HIGH254.50260.00260.00288.50304.50380.40447.00304.50
LOW241.20217.70202.80202.80180.40160.50160.50202.80

Dividende

pro Aktie
GENMAB does not deliver dividend information

Company profile

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.